SHR 2010
Alternative Names: SHR-2010Latest Information Update: 26 Jun 2023
At a glance
- Originator Guangdong Hengrui Pharmaceutical
- Class Urologics
- Mechanism of Action MASP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II IgA nephropathy
Most Recent Events
- 04 Jun 2023 Phase-II clinical trials in IgA nephropathy (In adults, In the elderly) in China (Parenteral) (NCT05847920)
- 11 May 2023 Guangdong Hengrui Pharmaceutical plans a phase II trial in primary IgA nephropathy (In adults, In the elderly) (Parenteral Injection) in May 2023 (NCT05847920)
- 01 Mar 2023 Guangdong Hengrui Pharmaceutical completes a phase I trial for IgA nephropathy (In volunteers, In adults) (IV, Injection), (SC, Injection) (NCT05398510)